NASDAQ:BMRN
BioMarin Pharmaceutical Inc. Stock Signals
Latest Data & Signals Issued
Signal Type | Signal Value | Data | |
---|---|---|---|
Score | -2.540 | 17 days ( 9.37 % ) | |
Last Price | $90.74 | 0.699 % | |
High/ Low | $89.34 - $91.16 | 0.750% | |
Chg 7 Days | -1.01 % | $91.67 $90.74 | |
Chg 30 Days | -12.01 % | $103.12 $90.74 | |
Chg 12 mos | 12.19 % | $80.88 $90.74 | |
Trend - 3 mos | -16.63 % | Width: 21.67 % | |
Trend - 12 mos | 31.97 % | Width: 37.61 % | |
Pred. range - 3 mos | $71.14 - $86.55 | -21.61 % - -4.62 % | |
Pred. range - 12 mos | $116.88 - $160.84 | 28.81 % - 77.25 % | |
Short mv avg 3 mos | Sell | 2023-03-21 - 4 days | |
Long mv avg 3 mos | Sell | 2023-02-09 - 31 days | |
Short/Long mv avg 3 mos | Sell | 2023-02-14 - 28 days | |
Short mv avg 12 mos | Buy | 2023-03-20 - 5 days | |
Long mv avg 12 mos | Sell | 2023-02-27 - 20 days | |
Short/Long mv avg 12 mos | Sell | 2023-03-07 - 14 days | |
Pivot Short | Sell | 2023-03-15 - 8 days | |
Bollinger | Buy | 2023-03-07 - 14 days | |
MACD | Buy | No Dates Stored For This Signal |
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o... BMRN Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.